EBE – the European Trade Association representing biopharmaceutical companies of all sizes.
About EBE
05 Dec 2017

Escher Study Identifies Hurdles to ATMP Development in Europe

First results of a study into factors associated with successful development of Advanced Therapy Medicinal Products (ATMPs) were reported today by Utrecht University at European Biopharmaceuti...

Read more
23 Nov 2017

EBE and EFPIA call for policy support to make personalised medicine a reality for patients

Ahead of the first congress of the European Alliance for Personalised Medicine (EAPM) “Personalising your health: A global imperative!” on 27-30 November 2017 in Belfast, the Joint EBE-EFPIA Perso...

Read more
10 Oct 2017

EBE and EFPIA call on the EU Commission and Member States to improve transparency on Hospital Exemptions for Advanced Therapies

“Therapies for the future - Exploring solutions for innovative treatments in Europe” will take place at the European Parliament  on 11 October 2017. In advance of this significant discussion...

Read more
15 Jan 2018

EBE reflection paper on “Medicinal product incorporating a drug delivery device component: An Industry Perspective on the EU marketing application technical requirements, regulatory review process and post-approval device related change assessment”

Within the European Biopharmaceutical Enterprises (EBE), a working group focused on EU specific topics relating to those integral combination products, which are regulated as medicinal products but wh...

Read more
19 Dec 2017

EFPIA-EBE White Paper: Expedited CMC Development- Accelerated Access for Medicines of Unmet Medical Need

Since 2012 there has been a focus on faster translation of scientific breakthroughs to new, high quality medicines meeting unmet medical need through a programme initially referred to as Medicines Ada...

Read more
14 Dec 2017

The associations representing the European and British life science industry have today launched a joint policy document on the potential impact of the United Kingdom’s exit the European Union

The associations representing the European and British life science industry (AESGP, ABPI, BIA, BGMA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have today launche...

Read more
15 Dec 2017

Incentives for Innovation. Incentivising Research in Areas of High Unmet Medical Need: Lilly’s Alzheimer’s Quest

With over 7,000 medicines in development, new treatments will continue to change patients’ lives, slowing disease progression, avoiding illness and reducing overall costs for healthcare systems....

Read more
12 Dec 2017

Presentations from the 6th EBE Annual Conference on ATMPs – 5 December 2017, London

The remarkable opportunities that cell and gene therapies can offer, but also the seemingly increasing number of obstacles to their wide application, were presented to a full audience in London’...

Read more
07 Dec 2017

Incentives, IP and smaller companies: the story of Lysogene

How Lysogene contributes to improving health outcomes Founded in France in 2009, and employing 18 staff at the end of 2017, Lysogene specialises in gene therapy targeting rare, neurod...

Read more

From Twitter

#WeWontRest until the pathway to personalised medicines for patients is clear https://t.co/MTnvjbTCev @EBE_EU

Da Volterra Announces Publication of Full Results from Clinical Trial of DAV132 in Healthy Volunteers to Prevent the Disruption of the Microbiome by Antibiotics in the Journal of Infectious Diseases https://t.co/M1MoT1M0el #antibody #antimicrobialresistance @DaVolterra

Our sincere thanks to @eurordis for this and congratulations particularly to @MagdaEfpia and her Team @EFPIA 👏🏻👏🏻👏🏻🌟 https://t.co/3IOoFJwWcH

Follow us